ICCC Q2 2019 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-10.1% YoY

Gross Profit

$1M46.1% margin

Operating Income

-$547,000-20.2% margin

Net Income

-$627,000-23.1% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-38.6%

Cash Flow

Operating Cash Flow

-$330,658

Free Cash Flow

-$436,391

Stock-Based Comp.

$70,081

Balance Sheet

Total Assets

$39M

Total Liabilities

$10M

Stockholders' Equity

$30M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	-10.1%
Gross Profit	$1M	$1M	-16.0%
Operating Income	-$547,000	-$193,409	-182.8%
Net Income	-$627,000	-$798,363	+21.5%